Home Biosimilar Antibodies Immunology & Inflammation Interleukins Ixekizumab (Anti-CTLA-8 / IL-17a)
For research use only. Not for use in humans.

Ixekizumab (Anti-CTLA-8 / IL-17a)

Synonyms: LY2439821

Ixekizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab has the potential to be used in research on plaque psoriasis. MW: 146.44 KD.

Ixekizumab (Anti-CTLA-8 / IL-17a)

Quality Control

Batch: Purity: 99% Protein concentration: 7.307mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 1
JTE-607 Dihydrochloride 2 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 6 PIKfyve
MD2-TLR4-IN-1 2 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 65 TLR4,NO,TNF-α
Apilimod (STA-5326) 19 PIKfyve
LMT-28 1
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 5
Diethyl phosphate 1
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 2 iNOS,TNF-α,PGE2
PKR-IN-C16 9 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 1 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 23 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 TNFα,MCP-1/CCL2,NOX2
AUDA 1 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 3 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 2 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 16
Methylthiouracil 1 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ixekizumab (Anti-CTLA-8 / IL-17a) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab has the potential to be used in research on plaque psoriasis. MW: 146.44 KD.
References

Product Details

CAS No. 1143503-69-8
Molecular Weight 146.44
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07352566 NOT_YET_RECRUITING Drug: Triamcinolone|Drug: 5-Fluorouracil|Drug: Calcipotriene Psoriasis; Atopic Dermatitis University of California, San Francisco 2026-08-01 PHASE4
NCT07704190 NOT_YET_RECRUITING Cardiorenal Metabolic Syndrome; Atherosclerotic Cardiovascular Disease; Chronic Kidney Disease; Coronary Artery Disease; Hypertension; Type 2 Diabetes Mellitus; Peripheral Arterial Disease; Carotid Artery Stenosis Peking University Third Hospital 2026-07-15 PHASE4
NCT06857942 RECRUITING Drug: Tirzepatide Psoriasis; Overweight or Obesity Eli Lilly and Company 2025-03-19 PHASE4
NCT06398106 RECRUITING Drug: Proactive TDM-based dosing of secukinumab|Drug: Proact Psoriasis Vulgaris University Hospital, Ghent 2024-12-20 PHASE4
NCT07443956 RECRUITING Drug: Ixekizumab|Drug: Tirzepatide Psoriatic Arthritis (PsA); Obesity & Overweight NHS Greater Glasgow and Clyde 2026-03-09
NCT07138898 RECRUITING Drug: Methotrexate|Drug: Sulfasalazine|Drug: Hydroxychloroqu Rheumatic Disease NYU Langone Health 2025-12-12 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.